β-methyl-4-nitrocinnamic acid | 80854-59-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: β-methyl-4-nitrocinnamic acid
• 英文别名: 3-(4-nitro-phenyl)-crotonic acid；4-Nitro-β-methyl-zimtsaeure；3-(4-Nitro-phenyl)-crotonsaeure；α-Methyl-p-nitro-cinnamic acid；p-Nitro-β-methyl-zimtsaeure；3-(4-Nitrophenyl)-2-butenoic Acid；3-(4-nitrophenyl)but-2-enoic acid
• CAS: 80854-59-7
• 化学式: C₁₀H₉NO₄
• mdl: MFCD25967407
• 分子量: 207.186
• InChiKey: APEDXSVBRQSCED-UHFFFAOYSA-N

物化性质

• 熔点：
  168-169 °C
• 沸点：
  341.8±11.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  β-methyl-4-nitrocinnamic acid 在 ammonium sulfide 作用下， 生成 3-(4-amino-phenyl)-crotonic acid
  参考文献：
  名称：

  Schroeter, Chemische Berichte, 1907, vol. 40, p. 1595

  摘要：

  DOI：
• 作为产物：
  描述：

  3-苯基丁-2-烯酸 在 硫酸 、 硝酸 作用下， 生成 β-methyl-4-nitrocinnamic acid
  参考文献：
  名称：

  Schroeter; Wuelfing, Chemische Berichte, 1907, vol. 40, p. 1594

  摘要：

  DOI：

文献信息

• Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition
  作者：Kim Y. P. Apperley、Isabelle Roy、Vincent Saucier、Nicholas Brunet-Filion、Sara-Pier Piscopo、Christophe Pardin、Élise De Francesco、Catherine Hao、Jeffrey W. Keillor

  DOI：10.1039/c6md00565a

  日期：——

  Starting from known reversible inhibitor CP4d, we have designed two new classes of inhibitors, improving both potency (22b) and glutathione resistance (27d).

  从已知的可逆抑制剂CP4d开始，我们设计了两类新的抑制剂，提高了两者的效力(22b)和对谷胱甘肽的抵抗力(27d)。
• Studies in decarboxylation. Part 16. Steric inhibition of resonance in a 1,5-sigmatropic reaction
  作者：Amal al-Borno、David B. Bigley

  DOI：10.1039/p29830001311

  日期：——

  The rates of gas-phase decarboxylation of some 3-phenyl-substituted but-3-enoic acids are best rationalized in terms of steric inhibition of resonance in the more sterically crowded members.

  就空间更拥挤的成员的共振的空间抑制而言，一些3-苯基取代的丁-3-烯酸的气相脱羧速率是最合理的。
• Room temperature decarboxylative trifluoromethylation of α,β-unsaturated carboxylic acids by photoredox catalysis
  作者：Pan Xu、Ablimit Abdukader、Kaidong Hu、Yixiang Cheng、Chengjian Zhu

  DOI：10.1039/c3cc48598f

  日期：——

  A visible-light-induced decarboxylative trifluoromethylation of alpha,beta-unsaturated carboxylic acids, which uses the Togni reagent as the CF3 source is disclosed. The corresponding trifluoromethylated alkenes were obtained in moderate to high yields with excellent functional group tolerance at ambient temperature. Preliminary mechanistic analyses suggest a radical-type mechanism.

  公开了使用Togni试剂作为CF 3源的可见光诱导的α，β-不饱和羧酸的脱羧三氟甲基化。以中等至高产率获得了相应的三氟甲基化烯烃，其在环境温度下具有优异的官能团耐受性。初步的机械分析表明是一种激进型机制。
• Viral polymerase inhibitors
  申请人：Beaulieu Louis Pierre

  公开号：US20060160798A1

  公开（公告）日：2006-07-20

  An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR 1 , or CR 1 , wherein R 1 is defined herein; represents either a single or a double bond; R 2 is selected from 6 or 10-membered aryl and Het, each optionally substituted with R 20 ; provided that Het is not a 5- or 6-membered monocyclic heterocycle having 1 or 2 nitrogen heteroatoms; B is NR 3 or CR 3 , with the proviso that one of A or B is either CR 1 or CR 3 , wherein R 3 is defined herein; K is N or CR 4 , wherein R 4 is defined herein; L is N or CR 5 , wherein R 5 has the same definition as R 4 ; M is N or CR 7 , wherein R 7 has the same definition as R 4 ; Y 1 is O or S; Z is N(R 6a )R 6 or OR 6 , wherein R 6a is H or alkyl or NR 61 R 62 wherein R 61 and R 62 are defined herein; and R 6 is H, alkyl, cycloalkyl, alkenyl, Het, alkyl-aryl, alkyl-Het; or R 6 is wherein R 7 and R 8 and Q are as defined herein; Y 2 is O or S; R 9 is H, (C 1-6 alkyl), (C 3-7 )cycloalkyl or (C 1-6 )alkyl-(C 3-7 )cycloalkyl, aryl, Het, (C 1-6 )alkyl-aryl or (C 1-6 )alkyl-Het, all of which optionally substituted with R 90 ; or R 9 is covalently bonded to either of R 7 or R 8 to form a 5- or 6-membered heterocycle; a salt or a derivative thereof, as an inhibitor of HCV NS 5 B polymerase.

  化合物的异构体、对映异构体、非对映异构体或互变异构体，由式I表示：其中：A是O、S、NR1或CR1，其中R1的定义如下；表示单键或双键；R2选自6或10元芳基和Het，每个可选择用R20取代；但是，Het不是具有1或2个氮杂原子的5-或6元单环杂环；B是NR3或CR3，但其中A或B之一是CR1或CR3，其中R3的定义如下；K是N或CR4，其中R4的定义如下；L是N或CR5，其中R5的定义与R4相同；M是N或CR7，其中R7的定义与R4相同；Y1是O或S；Z是N（R6a）R6或OR6，其中R6a为H或烷基或NR61R62，其中R61和R62的定义如下；而R6是H、烷基、环烷基、烯基、Het、烷基-芳基、烷基-Het；或R6是其中R7和R8和Q的定义如下；Y2是O或S；R9是H、（C1-6烷基）、（C3-7环烷基）或（C1-6烷基-（C3-7）环烷基）、芳基、Het、（C1-6烷基-芳基）或（C1-6烷基-Het），所有这些都可以选择用R90取代；或者R9与R7或R8中的任一种共价键结合形成5-或6元杂环；作为HCV NS5B聚合酶的抑制剂，其盐或衍生物。
• (Carboxy-oxo-pyrrolidino)phenylalkenamides and esters thereof as SRS-A
  申请人：Pfizer Inc.

  公开号：US04296120A1

  公开（公告）日：1981-10-20

  Certain new propenamide and 2-butenamide compounds, having a (4-carboxy-2-oxo-pyrrolidino)phenyl substituent at the 3-position, and certain esters thereof, and their use for antagonizing the spasmogenic activity of slow-reacting substance of anaphylaxis (SRS-A) in a human subject. In particular, the compounds of the invention are useful for preventing and treating certain obstructive airways diseases, notably allergic bronchial asthma, allergic rhinitis and certain skin disorders, in human subjects.

  某些新的丙烯酰胺和2-丁烯酰胺化合物，在3位具有（4-羧基-2-氧代吡咯烷基）苯基取代基，以及某些酯类化合物，用于拮抗人体内缓激肽反应物（SRS-A）的痉挛原性活性。特别地，本发明的化合物对于预防和治疗某些阻塞性呼吸道疾病，特别是过敏性支气管哮喘、过敏性鼻炎和某些皮肤疾病，在人体内有用。